TrialBreast (Edinburgh, Scotland)2022

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.

Paul Cottu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.